Integrated Multi‐Platform Profiling of Serum Bisphenol A and Circulating microRNAs With Comprehensive Biochemical Characterization Across Leukemia Subtypes

Leukemia accounts for ~3.1% of cancer burden in the world and there are no reliable noninvasive markers for subtyping and monitoring. The paper sought to characterize hematological, hepatic, renal, and cytokine profiles across the four major leukemia subtypes, quantify serum bisphenol A along with the profiling of three circulating microRNAs (miR‐34a, miR‐17, miR‐155), and integrate bisphenol A and microRNAs data into a unified biomarker framework using correlation and ROC analyses. The study was a case–control study, with 100 participants (80 cases and 20 healthy controls). The expression level of microRNAs was quantified using the RT‐qPCR technique (2 −ΔΔCt method, normalized to miR‐16‐5p). Mann–Whitney U , Kruskal–Wallis and binormal ROC analysis were used in the statistics. The biochemical characteristics of each of the subtypes were different: acute leukemias (ALL, AML) had severe cytopenias, coagulopathy, hepatic and renal impairment, and peak cytokine activity; CLL had extreme lymphocytosis and the highest β2‐microglobulin; CML had marked leukocytosis, thrombocytosis, and elevated vitamin B12. Serum bisphenol A was significantly elevated in all subtypes versus controls (6.12–8.44 vs. 2.30 ng/mL, p < 0.0001), with ROC AUCs of 0.770–0.842. miR‐34a was significantly suppressed in all the subtypes and miR‐17 and miR‐155 were constantly upregulated, with miRNA ROC AUCs ranging from 0.718 to 1.000 (91.7% excellent, ≥ 0.90). BPA was increased with IL‐6, ferritin and LDH and decreased with miR‐34a. A first cross‐subtype, cross‐platform analysis of all four leukemia subtypes suggests that a combined bisphenol A and miRNA signature is a promising noninvasive approach to leukemia detection, subtyping, and monitoring.

Authors

Institutions

Publication Details

Journal
Journal of Applied Toxicology
Published
2026-11-18
DOI
https://doi.org/10.1002/jat.70512
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrated Multi‐Platform Profiling of Serum Bisphenol A and Circulating microRNAs With Comprehensive Biochemical Characterization Across Leukemia Subtypes

Rebwar Muhammad Hamasalih, Saman Muhsin Abdulkareem, Mohammed Sharif H. Sulaiman
Journal of Applied Toxicology
Acute Lymphoblastic Leukemia research
article

Integrated Multi‐Platform Profiling of Serum Bisphenol A and Circulating microRNAs With Comprehensive Biochemical Characterization Across Leukemia Subtypes

Rebwar Muhammad Hamasalih, Saman Muhsin Abdulkareem, Mohammed Sharif H. Sulaiman
article en

Abstract

Leukemia accounts for ~3.1% of cancer burden in the world and there are no reliable noninvasive markers for subtyping and monitoring. The paper sought to characterize hematological, hepatic, renal, and cytokine profiles across the four major leukemia subtypes, quantify serum bisphenol A along with the profiling of three circulating microRNAs (miR‐34a, miR‐17, miR‐155), and integrate bisphenol A and microRNAs data into a unified biomarker framework using correlation and ROC analyses. The study was a case–control study, with 100 participants (80 cases and 20 healthy controls). The expression level of microRNAs was quantified using the RT‐qPCR technique (2 −ΔΔCt method, normalized to miR‐16‐5p). Mann–Whitney U , Kruskal–Wallis and binormal ROC analysis were used in the statistics. The biochemical characteristics of each of the subtypes were different: acute leukemias (ALL, AML) had severe cytopenias, coagulopathy, hepatic and renal impairment, and peak cytokine activity; CLL had extreme lymphocytosis and the highest β2‐microglobulin; CML had marked leukocytosis, thrombocytosis, and elevated vitamin B12. Serum bisphenol A was significantly elevated in all subtypes versus controls (6.12–8.44 vs. 2.30 ng/mL, p < 0.0001), with ROC AUCs of 0.770–0.842. miR‐34a was significantly suppressed in all the subtypes and miR‐17 and miR‐155 were constantly upregulated, with miRNA ROC AUCs ranging from 0.718 to 1.000 (91.7% excellent, ≥ 0.90). BPA was increased with IL‐6, ferritin and LDH and decreased with miR‐34a. A first cross‐subtype, cross‐platform analysis of all four leukemia subtypes suggests that a combined bisphenol A and miRNA signature is a promising noninvasive approach to leukemia detection, subtyping, and monitoring.

Journal of Applied Toxicology
Salahaddin University-Erbil (IQ)
Salahaddin University-Erbil
Good health and well-being
Acute Lymphoblastic Leukemia research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon